Dr. Andrea Apolo and patient
Rare tumors of the genitourinary tract can appear in the kidney, bladder, ureters and penis. Two drugs — sacituzumab govitecan and atezolizumab — are each approved to treat other cancers. A clinical trial led by Andrea B. Apolo, M.D., Senior Investigator in the Genitourinary Malignancies Branch, is researching if the two drugs used together can help people with rare genitourinary tract tumors.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for medical care received at the Clinical Center.
For more information, please contact Tzu-Fang Wang, R.N., at (240) 858-3236 or tzu-fang.wang@nih.gov.
Clinicaltrials.gov identifier: NCT06161532
NCI Protocol ID: IRB001535
Official Title: A Phase II Study of Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
